Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04633759
Other study ID # 20-0695
Secondary ID 205593
Status Completed
Phase N/A
First received
Last updated
Start date February 19, 2021
Est. completion date October 5, 2022

Study information

Verified date October 2022
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe walking problems. BFR training involves placing a cuff on the leg being exercised in order to restrict blood flow. The cuff is attached to a specialized device that automatically detects the appropriate amount of pressure to place on the limb. Testing will occur before and after the 8-week treatment period.


Description:

The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe walking problems. BFR training involves placing a cuff on the leg being exercised in order to restrict blood flow. The cuff is attached to a specialized device that automatically detects the appropriate amount of pressure to place on the limb. Testing will occur before and after the 8-week treatment period. Specific Aim 1: Determine the feasibility of BFR by assessing recruitment rate, retention, adherence, satisfaction, and safety. Hypothesis: Feasibility will be demonstrated by: 1) enrolling 20 participants in 8 months, 2) retaining at least 16 (80%) participants, 3) 80% adherence to intervention, 4) 90% satisfaction with intervention, and 5) no serious adverse events related to the intervention. Specific Aim 2: Determine changes in knee and hip extension, hip abduction, and ankle plantarflexion muscle strength after the 8-week intervention. Hypothesis: Following intervention there will be clinically important within-group strength changes that correspond to established minimal detectable change values and which can be characterized as having at least a moderate effect size as defined by Cohen's d. Exploratory Aim: Explore changes in functional mobility (30-Second Sit-to-Stand, Berg Balance Scale, Timed 25-Foot Walk. 10-day average activity level) and self-report measures (12-Item MS Walking Scale, Modified Fatigue Impact Scale, MS Impact Scale-29, and Patient-Specific Functional Scale) after the 8-week intervention.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date October 5, 2022
Est. primary completion date October 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Adults ages 18-70 - Neurologist-confirmed diagnosis of multiple sclerosis - Expanded Disability Status Scale (EDSS) 6.0 to 7.0 - EDSS 6.0: unilateral assistance (cane or crutch) required to walk at least 100 meters with or without resting - EDSS 6.5: Bilateral assistance (cane or crutch) required to walk at least 20 meters with or without resting - EDSS 7.0: unable to walk 5 meters even with aid, essentially restricted to wheelchair; wheels self and transfers alone; up and about in wheelchair some 12 hours a day Exclusion Criteria: - EDSS 7.5 or greater: Restricted to wheelchair for all mobility, unable to walk more than a few steps, even with walking aid - EDSS 5.5 or less: Able to walk more than 100 meters without walking aid or rest - Unable to provide consent or follow simple directions - Prior history of Deep Venous Thrombosis/ Pulmonary Embolism - History of peripheral vascular disease, thrombophilia or other clotting disorders - Patient report of easy bruising - Any comorbid conditions or pain that substantially affects physical function or would interfere with the participant's ability to safely complete rehabilitation (e.g. neurologic, vascular, cardiac problems, orthopedic, or ongoing medical treatments) as determined by a neurologist of physical therapist - Severe lower extremity spasticity as defined as Modified Ashworth scale > 2 - Currently undergoing supervised resistance training with a physical therapist or other exercise professional - Use of Blood Flow Restriction currently or in the previous 3 months prior to enrollment - MS-related exacerbation or changes to their disease-modifying drug therapy in the month prior to enrollment - Inability to tolerate pressure cuff during baseline assessment

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood Flow Restriction Exercise
Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.

Locations

Country Name City State
United States University of Colorado Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver Consortium of Multiple Sclerosis Centers

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in knee extension muscle strength Knee extension muscle strength measured by hand-held dynamometry Measured at Baseline (Week 0) and Post Test (Week 9)
Primary Change in hip abduction muscle strength Hip abduction muscle strength measured by hand-held dynamometry Measured at Baseline (Week 0) and Post Test (Week 9)
Primary Change in ankle plantarflexion muscle strength Ankle plantarflexion muscle strength measured by hand-held dynamometry Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in 30-second sit-to-stand completions Functional mobility test measuring the number of sit to stand cycles a participant can complete in 30 seconds Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in Berg Balance Scale Functional mobility test measuring the participant's ability to balance in different postures. Scores range from 0 to 56 points, with 0-20 points indicating wheelchair bound, 21-40 indicating walking with assistance, and 41-56 indicating walking independently. Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in timed 25-foot walk Functional mobility test measuring the time it takes a participant to walk 25 feet Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in activity level 10-day average of activity level as measured by a wearable activity monitor Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in 12-Item MS Walking Scale Self-report questionnaire measuring walking ability with scores ranging from 12 points (no difficulty walking, to 60 points (extremely limited or no walking) Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in Modified Fatigue Impact Scale Self-report questionnaire measuring fatigue caused by MS with scores ranging from 0 (no impact of fatigue in the past 4 weeks) to 84 (maximum impact of fatigue in the past 4 weeks) Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in MS Impact Scale-29 Self-report questionnaire measuring the impact of MS on daily activity with scores ranging from 29 (MS has no impact on my daily life) to 145 (MS extremely impacts my daily life) Measured at Baseline (Week 0) and Post Test (Week 9)
Secondary Change in MS Patient-Specific Function Scale Self-report questionnaire measuring the ability of the participant to do three self-identified activities. Scores of each of the 3 activities range from 0 (unable to perform) to 10 (able to perform without difficulty) Measured at Baseline (Week 0) and Post Test (Week 9)
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4